Market Overview

UPDATE: Bank of America Merrill Lynch Reinstates Coverage on Becton, Dickinson and Co.

Share:
Related BDX
Earnings Scheduled For February 2, 2017
7 Biotech And Healthcare Picks For 2017 From Cantor Fitzgerald

In a report published Monday, Bank of America Merrill Lynch reinstated coverage on Becton, Dickinson and Co. (NYSE: BDX) with an Underperform rating and $79.00 price target.

BofA Merrill Lynch noted, “After several years of pricing and margin pressure, we believe that BD can now deliver sustainable lowsingle digit organic revenue growth and modest margin expansion. However, as our organic revenue and EPS growth forecasts are well below historical levels, it is difficult to argue for further P/E multiple expansion. As such, we believe that BDX shares may underperform relative to peers, but note that the more defensive nature of the business likely offers downside protection.”

Becton, Dickinson and Co. closed on Friday at $77.72.

Latest Ratings for BDX

DateFirmActionFromTo
Jan 2017Raymond JamesDowngradesStrong BuyOutperform
Jan 2017JP MorganDowngradesOverweightNeutral
Sep 2016CitigroupDowngradesNeutralSell

View More Analyst Ratings for BDX
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Initiation Analyst Ratings

 

Related Articles (BDX)

View Comments and Join the Discussion!